RPRX

Royalty Pharma plc Class A Ordinary Shares

45.60

USD

RPRX Earnings Reports

Positive Surprise Ratio

RPRX beat 13 of 23 last estimates.

57%

Next Report

Date of Next Report

May 06, 2026

Estimate for Q1 26 (Revenue/ EPS)

$1.46B

$1.23

Implied change from Q4 25 (Revenue/ EPS)

+135.20%

-16.33%

Implied change from Q1 25 (Revenue/ EPS)

+74.36%

+89.23%

Royalty Pharma plc Class A Ordinary Shares earnings per share and revenue

On Feb 11, 2026, RPRX reported earnings of 1.47 USD per share (EPS) for Q4 25, beating the estimate of 1.35 USD, resulting in a 8.69% surprise. Revenue reached 621.99 million, compared to an expected 811.83 million, with a -23.38% difference. The market reacted with a +0.09% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 4 analysts forecast an EPS of 1.23 USD, with revenue projected to reach 1.46 billion USD, implying an decrease of -16.33% EPS, and increase of 135.20% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Alvotech Ordinary Shares

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.37

Surprise

-706.10%

Eton Pharmaceutcials, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

$0.09

Actual

$0.05

Surprise

-45.53%

XOMA Royalty Corporation Common Stock

Report Date

Mar 18, 2026 For Q4 25

Estimate

-$0.15

Actual

$0.12

Surprise

+175.90%

Cellectis S.A. - ADR

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.26

Actual

-$0.26

Surprise

+1.78%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

Eledon Pharmaceuticals, Inc. Common Stock

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$0.20

Actual

-$0.10

Surprise

+51.78%

Artiva Biotherapeutics, Inc. Common Stock

Report Date

Mar 30, 2026 For Q4 25

Estimate

-$0.84

Actual

Surprise

Milestone Pharmaceuticals Inc. Common Shares

Report Date

Mar 20, 2026 For Q4 25

Estimate

-$0.16

Actual

-$0.16

Surprise

+1.96%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

Pelthos Therapeutics Inc.

Report Date

Mar 19, 2026 For Q4 25

Estimate

-$4.21

Actual

-$2.83

Surprise

+32.82%

FAQ

What were Royalty Pharma plc Class A Ordinary Shares's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Royalty Pharma plc Class A Ordinary Shares reported EPS of $1.47, beating estimates by 8.69%, and revenue of $621.99M, -23.38% below expectations.

How did the market react to Royalty Pharma plc Class A Ordinary Shares's Q4 2025 earnings?

The stock price moved up 0.09%, changed from $44.21 before the earnings release to $44.25 the day after.

When is Royalty Pharma plc Class A Ordinary Shares expected to report next?

The next earning report is scheduled for May 06, 2026.

What are the forecasts for Royalty Pharma plc Class A Ordinary Shares's next earnings report?

Based on 4 analysts, Royalty Pharma plc Class A Ordinary Shares is expected to report EPS of $1.23 and revenue of $1.46B for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.